BeOne Medicines’ BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. IBM
3. PRIM
4. MU
5. DPZ
6. NAVN
7. DFTX
8. META
9. IMNN
10. ACN

Go back to BeOne Medicines’ BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma
Bank of Commerce (NASDAQ: ONC) Delayed: 271.80 --0 (-0%)
Previous Close $271.80    52 Week High $0.35 
Open $271.80    52 Week Low $0.35 
Day High $271.80    P/E N/A 
Day Low $271.80    EPS $0.00 
Volume 328